1. Mouri Y, Ueda Y, Yamano T, Matsumoto M, Tsuneyama K, Kinashi T, Matsumoto M.Mode of tolerance induction and requirement for aire are governed by the cell types that express self-antigen and those that present antigen. J Immunol. 2017 Dec 15;199(12):3959-3971.
2. Tsuneyama K, Nishitsuji K, Matsumoto M, Kobayashi T, Morimoto Y, Tsunematsu T, Ogawa H. Animal models for analyzing metabolic syndrome-associated liver diseases. Pathol Int. 2017 Nov;67(11):539-546.
3. Nishitsuji K, Xiao J, Nagatomo R, Umemoto H, Morimoto Y, Akatsu H, Inoue K, Tsuneyama K. Analysis of the gut microbiome and plasma short-chain fatty acid profiles in a spontaneous mouse model of metabolic syndrome. Sci Rep. 2017 Nov 20;7(1):15876.
4. Tsutsui A, Harada K, Tsuneyama K, Senoh T, Nagano T, Takaguchi K, Ando M, Nakamura S, Mizobuchi K, Kudo M. Clinicopathological study of autoimmune hepatitis cases that were difficult to differentiate from drug-induced liver injury. Dig Dis. 2017 Oct ;35(6):506-514.
5. Fujimoto Y, Tsuneyama K, Kuramoto N, Hayashi S, Yoshida N, Morioka A, Teramoto M, Nakajima H, Takeuchi T, Azuma YT. Exacerbated experimental pancreatitis in interleukin-19 knockout mice. Glob Drugs Therap. 2017 in press.
6. Tsuneyama K, Baba H, Matsumoto M, Kobayashi T, Morimoto Y, Tsunematsu T, Ogawa H. Effectiveness of new animal models for the analysis of metabolic syndrome-associated liver diseases. Patrol Int. 2017 in press
7. Nishijima H, Kajimoto T, Matsuoka Y, Mouri Y, Morimoto J, Matsumoto M, Kawano H, Nishioka Y, Uehara H, Izumi K, Tsuneyama K, Okazaki IM, Okazaki T, Hosomichi K, Shiraki A, Shibutani M, Mitsumori K, Matsumoto M. Paradoxical development of polymyositis-like autoimmunity through augmented expression of autoimmune regulator (AIRE). J Autoimmun. 2017 in press
8. Bae HR, Hodge DL, Yang GX, Leung PSC, Chodisetti SB, Valencia JC, Sanford M, Fenimore JM, Rahman ZSM, Tsuneyama K, Norman GL, Gershwin ME, Young HA. The interplay of type I and type II interferons in murine autoimmune cholangitis as a basis for sex-biased autoimmunity. Hepatology. 2017 in press
9. Baba H, Kurano M, Nishida T, Hatta H, Hokao R, Tsuneyama K. Facilitatory effect of insulin treatment on hepatocellular carcinoma development in diabetes. BMC Res Notes. 2017 Sep 13;10(1):478.
10. Nawaz A, Aminuddin A, Kado T, Takikawa A, Yamamoto S, Tsuneyama K, Igarashi Y, Ikutani M, Nishida Y, Nagai Y, Takatsu K, Imura J, Sasahara M, Okazaki Y, Ueki K, Okamura T, Tokuyama K, Ando A, Matsumoto M, Mori H, Nakagawa T, Kobayashi N, Saeki K, Usui I, Fujisaka S, Tobe K. CD206(+) M2-like macrophages regulate systemic glucose metabolism by inhibiting proliferation of adipocyte progenitors. Nat Commun. 2017 Aug 18;8(1):286.
11. Matsumoto K, Ichimura M, Tsuneyama K, Moritoki Y, Tsunashima H, Omagari K, Hara M, Yasuda I, Miyakawa H, Kikuchi K. Fructo-oligosaccharides and intestinal barrier function in a methionine-choline-deficient mouse model of nonalcoholic steatohepatitis. PLoS One. 2017 Jun 20;12(6):e0175406.
12. Takeuchi M, Matsuzaki K, Tsuneyama K, Nishimura M, Takiguchi E, Harada M. Ovarian Large Cell Neuroendocrine Carcinoma Associated with Serous Carcinoma: Correlation of Pathology with MR Imaging. Magn Reson Med Sci. 2017 Oct 10;16 (4):273-274.
13. Shimada S, Tajiri K, Baba H, Minemura M, Tsuneyama K, Nakano M, Sugiyama T. Peritumoral Hyperplasia in Hepatic Sclerosed Hemangioma. ACG Case Rep J. 2017 Apr 26;4:e61.
14. Nguyen Canh H, Harada K, Ouchi H, Sato Y, Tsuneyama K, Kage M, Nakano M, Yoshizawa K, Takahashi A, Abe M, Kang JH, Koike K, Inui A, Fujisawa T, Takaki A, Arinaga-Hino T, Torimura T, Suzuki Y, Fujiwara K, Zeniya M, Ohira H, Tanaka A, Takikawa H; Intractable Liver and Biliary Diseases Study Group of Japan. Acute presentation of autoimmune hepatitis: a multicentre study with detailed histological evaluation in a large cohort of patients. J Clin Pathol. 2017 Nov;70(11):961-969.
15. Ikutani M, Tsuneyama K, Kawaguchi M, Fukuoka J, Kudo F, Nakae S, Arita M, Nagai Y, Takaki S, Takatsu K. Prolonged activation of IL-5-producing ILC2 causes pulmonary arterial hypertrophy. JCI Insight. 2017 Apr 6;2(7):e90721.
16. Tsuneyama K, Baba H, Morimoto Y, Tsunematsu T, Ogawa H. Primary Biliary Cholangitis: Its Pathological Characteristics and Immunopathological Mechanisms. J Med Invest. 2017;64(1.2):7-13.
17. Watanabe S, Takahashi T, Ogawa H, Uehara H, Tsunematsu T, Baba H, Morimoto Y, Tsuneyama K. Daily Coffee Intake Inhibits Pancreatic Beta Cell Damage and Nonalcoholic Steatohepatitis in a Mouse Model of Spontaneous Metabolic Syndrome, Tsumura-Suzuki Obese Diabetic Mice. Metab Syndr Relat Disord. 2017 May;15(4):170-177.
18. Chang C, Lleo A, Kananurak A, Grizzi F, Tsuneyama K, Invernizzi P, Bevins CL, Bowlus CL. Human β-Defensin 2 in Primary Sclerosing Cholangitis. Clin Transl Gastroenterol. 2017 Mar 16;8(3):e80.
19. Shirai Y, Oda S, Makino S, Tsuneyama K, Yokoi T. Establishment of a mouse model of enalapril-induced liver injury and investigation of the pathogenesis. Lab Invest. 2017 Jul;97(7):833-842.
20. Ma HD, Ma WT, Liu QZ, Zhao ZB, Liu MZ, Tsuneyama K, Gao JM, Ridgway WM, Ansari AA, Gershwin ME, Fei YY, Lian ZX. Chemokine receptor CXCR3 deficiency exacerbates murine autoimmune cholangitis by promoting pathogenic CD8(+) T cell activation. J Autoimmun. 2017 Mar;78:19-28.
21. Ichimura M, Masuzumi M, Kawase M, Sakaki M, Tamaru S, Nagata Y, Tanaka K, Suruga K, Tsuneyama K, Matsuda S, Omagari K. A diet-induced Sprague-Dawley rat model of nonalcoholic steatohepatitis-related cirrhosis. J Nutr Biochem. 2017 Feb;40:62-69.
22. Oda S, Shirai Y, Akai S, Nakajima A, Tsuneyama K, Yokoi T. Toxicological role of an acyl glucuronide metabolite in diclofenac-induced acute liver injuly in mice. J Appl Toxicol. 2017 may;37(5):545-553.
23. Kawashita Y, Morine Y, Ikemoto T, Saito Y, Iwahashi S, Yamada S, Higashijima J, Imura S, Ogawa H, Yagi T, Shimada M. Loss of Fbxw7 expression is a predictor of recurrence in colorectal liver metastasis. J Hepatobilliary Pancreat Sci. 2017 Aug;24:576-583.
24. Nakano A, Ogawa H, Nakanishi Y, Fujita H, Mahara F,Shiogama K, Tsutsumi Y,Takeichi T. Hemophagocytic lymphohistiocytosis in a fatal case of severe fever with thrombocytopenia syndrome. Internal Medcine. 2017;56: 1597-1602.
25. Sato S, Shinohara S, Hayashi S, Morizumi S, Abe S, Okazaki H, Chen Y, Goto H, Aono Y, Ogawa H, Koyama K, Nishimura H, Kawano H, Toyoda Y, Uehara H, Nishioka Y. Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity. Respir Res 2017;18(1):172.